These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 30192155)

  • 21. Cost-utility of adjuvant high-dose interferon alpha therapy in stage III cutaneous melanoma in Quebec.
    Crott R; Ali F; Burdette-Radoux S
    Value Health; 2004; 7(4):423-32. PubMed ID: 15449634
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Economic analysis of adjuvant therapy with interferon alpha-2a in stage II malignant melanoma.
    Lafuma A; Dreno B; Delaunay M; Emery C; Fagnani F; Hieke K; Bonerandi JJ; Grob JJ;
    Eur J Cancer; 2001 Feb; 37(3):369-75. PubMed ID: 11239759
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A cost-effectiveness analysis of trametinib plus dabrafenib as first-line therapy for metastatic BRAF V600-mutated melanoma in the Swiss setting.
    Matter-Walstra K; Braun R; Kolb C; Ademi Z; Dummer R; Pestalozzi BC; Schwenkglenks M
    Br J Dermatol; 2015 Dec; 173(6):1462-70. PubMed ID: 26332527
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Post hoc economic analysis of temozolomide versus dacarbazine in the treatment of advanced metastatic melanoma.
    Hillner BE; Agarwala S; Middleton MR
    J Clin Oncol; 2000 Apr; 18(7):1474-80. PubMed ID: 10735895
    [TBL] [Abstract][Full Text] [Related]  

  • 25. NICE approves immunotherapy combination for advanced melanoma.
    Wise J
    BMJ; 2016 Jun; 353():i3421. PubMed ID: 27317590
    [No Abstract]   [Full Text] [Related]  

  • 26. Quality of life and cost-effectiveness of interferon-alpha in malignant melanoma: results from randomised trial.
    Dixon S; Walters SJ; Turner L; Hancock BW
    Br J Cancer; 2006 Feb; 94(4):492-8. PubMed ID: 16449995
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Direct costs associated with adverse events of systemic therapies for advanced melanoma: Systematic literature review.
    Copley-Merriman C; Stevinson K; Liu FX; Wang J; Mauskopf J; Zimovetz EA; Chmielowski B
    Medicine (Baltimore); 2018 Aug; 97(31):e11736. PubMed ID: 30075584
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessment of costs associated with adverse events in patients with cancer.
    Wong W; Yim YM; Kim A; Cloutier M; Gauthier-Loiselle M; Gagnon-Sanschagrin P; Guerin A
    PLoS One; 2018; 13(4):e0196007. PubMed ID: 29652926
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Descriptive study of the costs of diagnosis and treatment of cutaneous melanoma].
    Almazán-Fernández FM; Serrano-Ortega S; Moreno-Villalonga JJ
    Actas Dermosifiliogr; 2009 Nov; 100(9):785-91. PubMed ID: 19889300
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hospitalisation costs of metastatic melanoma in France; the MELISSA study (MELanoma In hoSpital coSts Assessment).
    Fernandes J; Bregman B; Combemale P; Amaz C; de Léotoing L; Vainchtock A; Gaudin AF
    BMC Health Serv Res; 2017 Aug; 17(1):542. PubMed ID: 28789648
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Economic burden of selected adverse events in patients aged ≥65 years with metastatic renal cell carcinoma.
    Hagiwara M; Hackshaw MD; Oster G
    J Med Econ; 2013 Nov; 16(11):1300-6. PubMed ID: 24004437
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Economic impact of healthcare resource utilisation patterns among patients diagnosed with advanced melanoma in the United Kingdom, Italy, and France: results from a retrospective, longitudinal survey (MELODY study).
    Johnston K; Levy AR; Lorigan P; Maio M; Lebbe C; Middleton M; Testori A; Bédane C; Konto C; Dueymes A; Sbarigia U; van Baardewijk M
    Eur J Cancer; 2012 Sep; 48(14):2175-82. PubMed ID: 22480965
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current systemic therapies for melanoma.
    Palathinkal DM; Sharma TR; Koon HB; Bordeaux JS
    Dermatol Surg; 2014 Sep; 40(9):948-63. PubMed ID: 25072125
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advanced cutaneous malignant melanoma: a systematic review of economic and quality-of-life studies.
    Cashin RP; Lui P; Machado M; Hemels ME; Corey-Lisle PK; Einarson TR
    Value Health; 2008; 11(2):259-71. PubMed ID: 18380638
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sequential treatment approaches in  the management of BRAF wild-type advanced melanoma: a cost-effectiveness analysis.
    Tarhini A; Benedict A; McDermott D; Rao S; Ambavane A; Gupte-Singh K; Sabater J; Ritchings C; Aponte-Ribero V; Regan MM; Atkins M
    Immunotherapy; 2018 Oct; 10(14):1241-1252. PubMed ID: 30175642
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment patterns and outcomes among patients with metastatic melanoma treated in community practice.
    Walker MS; Reyes C; Kerr J; Satram-Hoang S; Stepanski EJ
    Int J Dermatol; 2014 Nov; 53(11):e499-506. PubMed ID: 24602078
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Melanoma costs: a dynamic model comparing estimated overall costs of various clinical stages.
    Alexandrescu DT
    Dermatol Online J; 2009 Nov; 15(11):1. PubMed ID: 19951637
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness analysis of interferon as adjuvant therapy in high-risk melanoma patients in Spain.
    González-Larriba JL; Serrano S; Alvarez-Mon M; Camacho F; Casado MA; Díaz-Pérez JL; Díaz-Rubio E; Fosbrook L; Guillem V; López-López JJ; Moreno-Nogueira JA; Toribio J
    Eur J Cancer; 2000 Dec; 36(18):2344-52. PubMed ID: 11094308
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment patterns, comorbidities, healthcare resource use, and associated costs by line of chemotherapy and level of comorbidity in patients with newly-diagnosed Merkel cell carcinoma in the United States.
    Kearney M; Thokagevistk K; Boutmy E; Bharmal M
    J Med Econ; 2018 Dec; 21(12):1159-1171. PubMed ID: 30149739
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Estimated Healthcare Costs of Melanoma in Australia Over 3 Years Post-Diagnosis.
    Elliott TM; Whiteman DC; Olsen CM; Gordon LG
    Appl Health Econ Health Policy; 2017 Dec; 15(6):805-816. PubMed ID: 28756584
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.